non-small cell lung cancer Sep 20, 2022 Elicio Receives $2.8M Grant for Cancer Vaccine Development Sep 14, 2022 FDA Clears Anbogen Therapeutics to Study ABT-101 in HER2-Mutant NSCLC Patients in the US Sep 13, 2022 ESMO Data Deepens Understanding of KRAS Inhibitor Activity in Lung, Colorectal Cancer Premium Sep 11, 2022 ESMO Study Explores Role of Air Pollution in EGFR-Mutant NSCLC in Non-Smokers Premium Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Sep 9, 2022 Roche Obtains CE Mark for Ventana PD-L1 Assay as CDx for Libtayo Sep 2, 2022 Jacobio Pharma Doses First NSCLC Patient in JAB-21822 Trial in China Aug 31, 2022 Amgen's Lumakras Bests Chemo, Meets Primary Endpoint in CodeBreak 200 Trial Aug 30, 2022 Jounce Therapeutics' Vopratelimab, Pimivalimab Combo Trial in NSCLC Fails to Meet Primary Endpoint Aug 30, 2022 Thermo Fisher Scientific Obtains CE-IVD Mark for Targeted NGS Oncology Test, Analysis Software Aug 29, 2022 RedCloud Begins Phase I/IIa Trial in EGFR TKI-Resistant Lung Cancer Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 24, 2022 Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq Aug 23, 2022 Erasca, MD Anderson Cancer Center Partner to Study ERK, SHP2 Inhibitors Aug 12, 2022 AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer Aug 11, 2022 Novartis' Tabrecta Nets Full FDA Approval for NSCLC With METex14 Skipping Mutations Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Aug 10, 2022 Mount Sinai Using $500K Grant to Study KRAS-Mutant Lung Cancer Treatments Aug 9, 2022 Amgen Finetuning Combination Strategy for Lumakras in NSCLC Following Safety Readouts Premium Aug 9, 2022 GSK, Mersana Therapeutics Ink $100M Option Agreement for Antibody-Drug Conjugate Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
